Blood test can detect cancer 18 months before symptoms appear
A new blood test means it is now possible to detect cancer up to 18 months before symptoms even appear. Test for Cancer has launched the HrC Genomics blood test, a non-invasive screening tool designed to spot cancer before it becomes symptomatic, reducing the need for invasive procedures like tissue biopsies.
With cancer among the world's leading causes of death, early detection remains one of the most effective ways to improve outcomes. But many cancers are diagnosed too late, when treatment options are more limited and survival rates are lower.
Test for Cancer says its new test can change that. By identifying specific stem cells that begin circulating when cancer is present, even before symptoms emerge, the HrC Genomics test offers a way to screen for cancer much earlier than standard approaches allow.
READ MORE: Cardiologists name two foods that lower cholesterol 'just like statins'
READ MORE: Neurologist says you can cut cholesterol, blood pressure and dementia risk in 20 minutes
According to the organisation, these cells, known as pluripotent progenitor stem cells, can be detected in the blood as early as 12 to 18 months before any signs of illness. That early window gives patients and doctors more time to intervene and improves the chances of successful treatment.
The test is available to adults of all ages and is not limited by gender or family history, making it a potentially powerful screening option for people who might not otherwise qualify for routine checks. Test for Cancer says its mission is to make early cancer detection more widely accessible, helping more people take control of their health and catch cancer before it advances.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
35 minutes ago
- Medscape
Which Immunoglobulin Route Best Prevents Infections?
TOPLINE: In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection rates than the intravenous and facilitated subcutaneous routes. METHODOLOGY: Researchers conducted a cross-sectional study to compare the incidence of viral infections among immunocompromised patients who had been receiving IRT via different administration routes for more than 5 years. They included 58 patients (56.8% boys; median age, 17 years; median age at diagnosis, 11.5 years) with inborn errors of immunity. The intravenous route was the most common route of immunoglobulin administration (n = 32), followed by the conventional subcutaneous (n = 16) and facilitated subcutaneous (n = 10) routes. Patients underwent monitoring of immunoglobulin levels and had nasal swab collected monthly, with viral infections recorded when symptoms such as runny nose, cough, or fever were present. Infections from different immunoglobulin administration routes were analyzed by polymerase chain reaction testing of nasal swabs and serum immunoglobulin levels using nephelometry. TAKEAWAY: The overall viral infection frequency was 3.79%, with rates of 4.2% for the intravenous route, 2.5% for the conventional subcutaneous route, and 4.4% for the facilitated subcutaneous route of immunoglobulin administration. The conventional subcutaneous route associated with significantly lower infection rates than the other routes (P < .05). Adenovirus (21.8%), influenza A virus (16.4%), and human rhinovirus/enterovirus (16.4%) were the most frequently detected viral agents. At 3 months, patients with X-linked agammaglobulinemia (6.06%) and those with common variable immunodeficiency (3.65%) had the highest rates of viral infections. IN PRACTICE: 'Shared decision-making between patients and healthcare professionals is critical in determining the most appropriate administration route and product to minimize the risk of infections and achieve optimal treatment outcomes,' the authors wrote. SOURCE: The study was led by Hulya Kose, Department of Pediatric Immunology and Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey. It was published online on May 30, 2025, in the European Journal of Pediatrics. LIMITATIONS: This research had limitations due to the small sample size within specific patient subgroups. DISCLOSURES: The study did not receive any specific funding. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Associated Press
an hour ago
- Associated Press
PathAI Receives FDA Clearance for AISight® Dx Platform for Primary Diagnosis
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx *—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform's continuous innovation and PathAI's commitment to delivering enhanced capabilities as the product evolves. The FDA decision also included a Predetermined Change Control Plan (PCCP), enabling PathAI to validate and implement specified major changes such as additional displays, scanners, file formats and browsers into AISight Dx without requiring additional 510(k) submissions. This proactive regulatory alignment accelerates future software updates and hardware integrations, allowing faster innovation while ensuring continued FDA compliance. AISight Dx is a cloud-native digital pathology platform designed to maximize efficiency in anatomic pathology workflows. From intelligent case management to high-performance slide review and seamless live collaboration, AISight Dx helps labs accelerate turnaround times and optimize pathologist productivity. With integrated image management, synchronized multi-slide navigation, and robust annotation tools, the platform eliminates manual bottlenecks and supports faster, more consistent diagnoses. Designed for interoperability, compliance, and scale, AISight Dx empowers anatomic pathology labs, hospital systems, and academic medical centers to modernize operations and deliver high-quality patient care with confidence. 'Digital pathology is the future of diagnostic medicine, empowering pathologists to work more efficiently and collaborate quickly without being limited to physical specimen review,' said Andy Beck, M.D., Ph.D., CEO of PathAI. 'This 510(k) clearance showcases our commitment to quality and scientific rigor at PathAI and provides us a way forward to continually enhance our AISight Dx IMS.' Learn more about AISight Dx here. * AISight® Dx is FDA-cleared (K243391) for primary diagnosis in the US with the Hamamatsu NanoZoomer® S360MD and Leica Aperio® GT 450 DX slide scanners, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of AI-powered pathology solutions that aim to improve the accuracy of histology assessment and accelerate drug development. PathAI's platform leverages advanced artificial intelligence to analyze and interpret pathology images, providing valuable insights to pathologists, researchers, and pharmaceutical companies. PathAI is headquartered in Boston, MA. For more information, please visit and follow us on LinkedIn. Company Contact Liz Storti Chief People Officer [email protected] Media Contact Owen Blaschak LifeSci Communications [email protected]
Forbes
an hour ago
- Forbes
Bright Future: Technology Leaders Look To Quantum
John Prisco, Security CEO & founder of Safe Quantum Inc., working with data-driven companies to develop and deploy quantum-safe technologies Amid the ongoing funding news for bright, young quantum startups (see Classiq, SilQ Connect), recent news from the U.S. Congress and established technology companies is raising the stakes for quantum viability and the need to keep Chinese quantum development within reach. Word on the street is that Nvidia plans to invest in PsiQuantum, the chipmaker's first direct tie to quantum hardware. The move is especially interesting considering the position of Nvidia CEO Jensen Huang, who said earlier this year that a viable quantum computer is still decades away. This move would extend Nvidia's ongoing interest in quantum, which includes quantum software development, a hybrid system framework and a new quantum research lab in Boston that will be devoted to leveraging AI-powered supercomputers alongside advanced quantum hardware. The Nvidia news comes on the heels of other big-name investments in quantum this year. Amazon joined the quantum party, nudging some of its chief cloud rivals like Google and Microsoft in the race for potential payoff when quantum goes commercial. Amazon touted its Ocelot quantum chip (announced a week after Microsoft's own) as a high-efficiency approach to quantum and extending the Amazon Web Services (AWS) cloud-computing platform. Microsoft doesn't plan to allow access to its chip through the Azure public cloud infrastructure, however, focusing instead on building the capacity of its chip to add qubits—quantum bits of data. The flurry of activity isn't a moment too soon if you look at China's movements in quantum. The Chinese announced in April a successful test of perfectly encrypted data communications over 750 miles, an extraordinary distance. It's yet another example of China's emerging dominance in quantum development, a potential threat so serious that Microsoft President Brad Smith warned it puts the United States in jeopardy of falling irrevocably behind. Smith has exhorted the current administration to prioritize quantum research, renewing programs such as the National Quantum Initiative Act and focusing on developing an educational pipeline initiative to cultivate quantum talent. Already this year, a bipartisan group of U.S. representatives banded together to introduce a sandbox program to complement the National Quantum Initiative. The Quantum Sandbox for Near-Term Applications Act aims to provide a cloud-based workspace for government and commercial researchers to experiment with quantum applications for defense, healthcare, energy and manufacturing. There are other bright spots. Cisco, at the heart of the existing internet infrastructure, announced a new quantum lab and the development of a quantum chip prototype designed to enable quantum networks to scale. IBM has partnered with Tata Consultancy Services to launch the largest quantum research and development center in India, alongside an IBM Quantum Systems Two installation with a 156-qubit Heron quantum processor. The Indian investment is on top of IBM's strategy to invest $150 billion (that's BILLION) in the United States over the next five years to expand U.S.-based manufacturing of quantum computers and mainframe systems. With the volume of investment in small and large technology companies, it's clear that quantum's future is calling. No doubt the next few years will also herald a time of mergers and acquisitions, as newer technologies come to market. Smart investors would do well to especially consider companies with a focus on early-stage quantum solutions, such as quantum key distribution (QKD), with proven use cases that deploy quantum today over existing fiber optic networks. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
